Devices not on FDA's agenda for MRA (mutual recognition agreement) meeting:
This article was originally published in Clinica
The FDA's first public meeting to discuss progress in implementing the mutual recognition agreement (MRA) between the US and the European Union will focus on the agreement as it relates to pharmaceuticals, and not medical devices. The agency initially wanted to discuss the medical device sectoral annex and the drugs sectoral annex of the accord at its December 8 meeting but changed its mind because of differences between the two, according to Charles Gaylord in the FDA office of international and constituent relations. No date has been set for a public meeting on the section of the agreement covering devices, but it will probably take place within a few months, he said.
You may also be interested in...
Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.